Published October 2021 | Version Accepted Version
Journal Article Open

Mechanisms of HCV resistance to broadly neutralizing antibodies

  • 1. ROR icon Johns Hopkins University
  • 2. ROR icon California Institute of Technology

Abstract

Broadly neutralizing antibodies (bNAbs) block infection by genetically diverse hepatitis C virus (HCV) isolates by targeting relatively conserved epitopes on the HCV envelope glycoproteins, E1 and E2. Many amino acid substitutions conferring resistance to these bNAbs have been characterized, identifying multiple mechanisms of bNAb escape. Some resistance substitutions follow the expected mechanism of directly disrupting targeted epitopes. Interestingly, other resistance substitutions fall in E2 domains distant from bNAb-targeted epitopes. These substitutions, which can confer broad resistance to multiple bNAbs, act by less clearly defined mechanisms. Some modulate binding of HCV to cell surface receptors, while others may induce conformational changes in the E2 protein. In this review, we discuss mechanisms of HCV bNAb resistance and implications for HCV vaccine development.

Additional Information

© 2021 Elsevier B.V. Available online 28 July 2021. This work was supported in part by by the National Institutes of Health grant R01 AI127469 (to JRB) and U.S. NIH grant K99 AI153465 (to AIF). Conflict of interest statement: Nothing declared.

Attached Files

Accepted Version - nihms-1728485.pdf

Files

nihms-1728485.pdf

Files (517.3 kB)

Name Size
md5:fdad8c533ce2be6228f59dc1cad231f9
517.3 kB Preview Download

Additional details

Identifiers

PMCID
PMC8500940
Eprint ID
110318
Resolver ID
CaltechAUTHORS:20210820-001717573

Funding

NIH
NIH

Dates

Created
2021-08-20
Created from EPrint's datestamp field
Updated
2023-07-07
Created from EPrint's last_modified field